

II. Sequence Rule Compliance

In response to the sequence rules, Applicants herein submit a new Sequence Listing, in both a paper copy for insertion into the specification, and in computer readable form.

The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labelled diskette, specifically the ASCII-encoded file therein labelled "SEQUENCE.TXT", is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. No new matter is added.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: 21 May 2001



Valeta A. Gregg, Reg. No. 35,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE